Shelton Capital Management boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 206,700 shares of the biopharmaceutical company’s stock after acquiring an additional 68,731 shares during the period. Gilead Sciences accounts for about 0.9% of Shelton Capital Management’s investment portfolio, making the stock its 20th largest position. Shelton Capital Management’s holdings in Gilead Sciences were worth $14,039,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rockland Trust Co. raised its stake in Gilead Sciences by 16.7% during the 1st quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after acquiring an additional 25,551 shares during the period. Seizert Capital Partners LLC raised its stake in Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after acquiring an additional 27,547 shares during the period. Linscomb & Williams Inc. raised its stake in Gilead Sciences by 3.0% during the 1st quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after acquiring an additional 154 shares during the period. Berkshire Asset Management LLC PA bought a new stake in Gilead Sciences during the 1st quarter worth approximately $270,000. Finally, Sigma Planning Corp raised its stake in Gilead Sciences by 7.7% during the 1st quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after acquiring an additional 2,889 shares during the period. Institutional investors own 74.05% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.43% during mid-day trading on Friday, hitting $85.10. The company had a trading volume of 11,611,092 shares. The company has a market capitalization of $111.13 billion, a P/E ratio of 9.24 and a beta of 1.19. The company has a 50-day moving average price of $75.84 and a 200 day moving average price of $69.71. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the business posted $3.08 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post $8.74 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
Several research firms have recently issued reports on GILD. Jefferies Group LLC reiterated a “hold” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 11th. BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price objective (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. J P Morgan Chase & Co reiterated an “overweight” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 4th. Leerink Swann reiterated a “market perform” rating on shares of Gilead Sciences in a research report on Thursday, June 22nd. Finally, BidaskClub upgraded shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Ten investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and an average target price of $83.06.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/09/10/gilead-sciences-inc-gild-holdings-raised-by-shelton-capital-management.html.
In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP James R. Meyers sold 60,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $83.19, for a total value of $4,991,400.00. Following the transaction, the executive vice president now owns 62,715 shares of the company’s stock, valued at $5,217,260.85. The disclosure for this sale can be found here. Insiders have sold a total of 414,999 shares of company stock valued at $32,335,540 over the last 90 days. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.